SCHEMBL13613453

SCHEMBL13613453

NC(=O)c1cnc(N)c2cc(-c3ccc(S(=O)(=O)N4CCOCC4)s3)sc12

nearest known ligand 0.62

Predicted protein targets (top 20)

geneUniProtsupporting neighboursconfidence
JAK2 O60674 10/20 0.62
JAK1 P23458 10/20 0.62
TYK2 P29597 10/20 0.62
JAK3 P52333 9/20 0.62
MAPT P10636 2/20 0.44
HSD17B10 Q99714 2/20 0.44
KDM4E B2RXH2 1/20 0.44
MEN1 O00255 1/20 0.44
USP2 O75604 1/20 0.44
KMT2A Q03164 1/20 0.44
SMN1; SMN2 Q16637 1/20 0.44
ALDH1A1 P00352 1/20 0.39
CYP1A2 P05177 1/20 0.39
POLB P06746 1/20 0.39
CYP3A4 P08684 1/20 0.39
GAA P10253 1/20 0.39
CYP2D6 P10635 1/20 0.39
CYP2C9 P11712 1/20 0.39
HPGD P15428 1/20 0.39
CYP2C19 P33261 1/20 0.39

Click a target to see other patent compounds predicted against it — the reverse direction, in place.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
SCHEMBL13613449 0.81 JAK2 (0.66) JAK2JAK1TYK2JAK3MAPT
SCHEMBL13606556 0.77 JAK2 (1.00) JAK2JAK1TYK2JAK3
SCHEMBL14468618 0.74 JAK2 (0.51) JAK2JAK1TYK2JAK3
SCHEMBL13613448 0.74 JAK2 (0.55) JAK2JAK1TYK2JAK3
SCHEMBL14468621 0.74 JAK2 (0.45) JAK2JAK1TYK2JAK3
SCHEMBL5458391 0.74 JAK2 (0.75) JAK2JAK1TYK2JAK3
SCHEMBL13613447 0.74 JAK2 (0.54) JAK2JAK1TYK2JAK3
SCHEMBL13606548 0.73 JAK2 (0.68) JAK2JAK1TYK2JAK3
SCHEMBL4495900 0.72 JAK2 (0.61) JAK2JAK1TYK2JAK3
SCHEMBL13613454 0.71 JAK2 (0.54) JAK2JAK1TYK2JAK3KDM4E

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 3 patents. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
US-7635695-B2 Antiinflammation agents AMGEN INC. (US) 2009-12-22 US disclosed
US-20070155777-A1 Antiinflammation agents AMGEN, INC. 2007-07-05 US disclosed
US-7199119-B2 Antiinflammation agents AMGEN INC. (US) 2007-04-03 US disclosed

Patent text — is the patent's own abstract consistent with the prediction?

For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.

PatentTitleText reads most aboutPredicted target · text-rank
US-20070155777-A1 Antiinflammation agents TNF, NFATC1, NFKBIA JAK2 1101/4885JAK1 1726/4885TYK2 2825/4885

“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.